Ionis Archives -

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its

Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial

https://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/

News/ News/ R&D

Roche stops dosing in trial of Huntington’s disease hopeful tominersen

Richard Staines Huntington's disease, Ionis, neurology, Roche 0 Comment

Roche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed

Roche stops dosing in trial of Huntington’s disease hopeful tominersen

https://pharmaphorum.com/news/roche-stops-dosing-in-huntingtons-disease-trial/

The diagnosis Hepatitis written on a clipboard

News/ News/ R&D/ Top stories

Ionis deal delivers for GSK as HBV drug hits the mark in phase 2

Phil Taylor antisense drugs, GlaxoSmithKline, hepatitis B, infectious disease, Ionis 0 Comment

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a

Ionis deal delivers for GSK as HBV drug hits the mark in phase 2

https://pharmaphorum.com/news/ionis-deal-delivers-for-gsk-as-hbv-drug-hits-the-mark-in-phase-2/

News/ News/ R&D

Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug

Richard Staines Akcea, Diabetes, Ionis, NASH, Pfizer 0 Comment

Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to

Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug

https://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/

News

Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US

Richard Staines Akcea, familial chylomicronemia syndrome, Ionis, Rare diseases 0 Comment

European regulators have recommended a licence for Akcea and Ionis’ ultra-rare disease drug Waylivra, a therapy that the

Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US

https://pharmaphorum.com/news/akcea-ionis-rare-disease-drug-waylivra-set-for-eu-market-after-rejection-in-us/

News/ News/ R&D

Novartis licenses lipoprotein-lowering CVD drug

George Underwood Akcea, cardiovascular, CVD, Ionis, Novartis 0 Comment

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment

Novartis licenses lipoprotein-lowering CVD drug

https://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/

News/ News/ R&D

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

Phil Taylor Akcea, Ionis, lipoprotein, Novartis 0 Comment

Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

https://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/

Market Access/ News/ News

Alnylam’s Onpattro is first ever FDA-approved RNAi drug

Richard Staines Alnylam, Ionis, Rare diseases 0 Comment

Onpattro will cost $450,000 a year

Alnylam’s Onpattro is first ever FDA-approved RNAi drug

https://pharmaphorum.com/news/alnylams-onpattro-first-ever-approved-rnai-drug/

News/ R&D/ Rare diseases

Alnylam hopes for 2018 filing for RNAi liver disease drug

Richard Staines Alnylam, Biotech, hepatology, Ionis, RNAi 0 Comment

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018

Alnylam hopes for 2018 filing for RNAi liver disease drug

https://pharmaphorum.com/news/alnylam-hopes-2018-filing-rnai-liver-disease-drug/

Trending

Ionis

Login